Genflow Biosciences Plc - GENFF stock
About[edit]
Genflow Biosciences plc, along with its subsidiaries, is a biotechnology company that is primarily focused on the development of biological interventions to address the effects of aging. Their goal is to slow down and potentially halt the aging process while reducing the prevalence of age-related diseases and promoting increased health span.[1] Genflow Biosciences plc is a biotech company headquartered in the UK, with research and development facilities in Belgium and a US office in Cambridge, MA. The company was established in 2021 and has its headquarters located in London, United Kingdom.[2]
OTC Markets[edit]
Genflow Biosciences Plc began trading on the OTCQB Venture Market in the United States under the symbol GENFF on June 13, 2023. The company was already trading on the London Stock Exchange ("LSE") Main Market under the symbol GENF. The inclusion on the OTCQB Venture Market did not involve any capital raising. [3]
Research and Development[edit]
Their primary goal is to develop therapeutics that have the potential to slow down or halt the aging process in both humans and dogs. The company's main focus is on a lead compound that involves delivering a variant of the SIRT6 gene, which has shown promising results in preclinical studies. With a team of experienced professionals who have extensive backgrounds in the pharmaceutical and biotechnology industries, Genflow Biosciences is hoping that their development programs will progress rapidly over the next two years.[2] Their leading compound is GF-1002, which is a suspension of an adeno-associated viral vector-based gene therapy that is administered through intravenous infusion. Additionally, Genflow Biosciences is working on the development of GF-3001, a topical delivery system of SIRT6 targeting the skin, and GF-4001, an anti-aging pipeline specifically designed for veterinary use in non-human animals.[1]
Genflow is actively engaged in the research, development, and safe implementation of its two longevity programs. By actively pursuing research and development in these areas, Genflow aims to address critical medical conditions and contribute to advancements in longevity science.[4]
- NASH (Non-Alcoholic Steatohepatitis): The company is dedicated to reversing the aging effects on fibrotic livers, aiming to restore them to normal functionality. NASH is a prevalent condition, affecting approximately 35 million individuals worldwide. It is a leading cause of chronic liver disease and necessitates liver transplants.
- Werner Syndrome: Genflow is committed to enhancing the quality of life for patients afflicted with this condition, which causes accelerated aging. The company is focused on facilitating swift first-in-human trials to assess the effectiveness of potential treatments for Werner Syndrome.
Sarcopenia Research Program with Revatis SA[edit]
Genflow, in partnership with Revatis SA, has initiated a three-year research program on sarcopenia, supported by a 1.34 million euro grant. Sarcopenia, the age-related decline in muscle mass and function, is a growing health concern that affects the elderly globally. This collaboration aims to broaden Genflow's research focus by exploring innovative solutions and gaining insights into the mechanisms of muscle deterioration. The partnership leverages the expertise of both companies to address the challenges posed by an aging population.[5]
mRNA Delivery Research with EXO Biologics[edit]
Genflow and EXO Biologics have launched a three-year scientific program funded by a 1.55 million euro grant. The project aims to develop a novel mRNA delivery system using exosomes to encapsulate and deliver Genflow's proprietary centenarian SIRT6 gene. This innovative approach leverages the natural benefits of exosomes, such as enhanced stability and reduced immunogenicity, to potentially revolutionize treatments for Werner Syndrome and other age-related conditions. This collaboration underscores Genflow's leadership in cutting-edge research.[5]
Patents[edit]
Genflow and its partners, including the University of Rochester, Columbia University, and Albert Einstein College of Medicine, received a patent in Europe for a potential treatment of diseases associated with aging. The patent focuses on "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases," highlighting SIRT6's role in DNA repair and longevity. Genflow's lead drug, GF-1002, which delivers a centenarian variant of SIRT6, is undergoing development to determine its potential benefits for conditions like non-alcoholic steatohepatitis (NASH).[6]
Funding[edit]
Grants[edit]
Genflow received grants, totaling nearly three million euros, in early 2024 from the Government of Wallonia in Belgium which are intended to be applied to collaborative research projects with Revatis SA and EXO Biologics. The grant money will be distributed based on the achievement of milestones in the projects.[5] The research programs are part of a largerr innovation initiative by the Walloon Government focused on Advanced Therapy Medicinal Products (ATMPs). This partnership, with an 81 million euro budget, is funded 60% by public funds and 40% by private contributions from various companies, spanning over three years. The initiative is a collaborative effort involving BioWin, the Health Cluster of Wallonia, and the Public Service of Wallonia, demonstrating a significant commitment to advancing medical research and development in the region.[5]
Placement April 2024[edit]
In April, 2024 Genflow raised £715,000 with the help of broker Capital Plus Partners. The funds were raised with the sales of 57.2 million shares. In addition, each share has a warrant attached which can be exercised within one year at a price of 2 pence.[7]
| OTC Tier: OTCQB | Related ticker symbols: LSE: GENF
- ↑ 1.0 1.1 Yahoo Finance. GENFF Stock Profile. Retrieved on 7/3/2023.
- ↑ 2.0 2.1 genflowbio.com. About. Retrieved on 7/2/2023.
- ↑ Accesswire. Genflow Biosciences PLC Announces Admittance to Trading on the OTCQB Venture Market. June 13, 2023.
- ↑ London Stock Exchange. Company Update April 2023. April 4, 2023.
- ↑ 5.0 5.1 5.2 5.3 Accesswire. Genflow Biosciences PLC Announces Two Non-Dilutive Research Grant Awards. January 18, 2024.
- ↑ Accesswire. Genflow Biosciences PLC Announces Publication of a Key European Patent. March 21, 2024.
- ↑ Yahoo Finance. Genflow Biosciences PLC Announces Successful Placing and Subscription. April 4, 2024.
